Noncontraceptive benefits of oral contraceptive use: An evidence-based approach

International Journal of Fertility and Women's Medicine

Volumn 45, Issue 3, 2000, Pages 241-247

  Williams, J Kell ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Acne; Bone mineral density; Noncontraceptive benefits; Oral contraceptives

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; BONE ATROPHY; CANCER RISK; DRUG EFFECT; DRUG USE; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MENSTRUATION DISORDER; ORAL CONTRACEPTION; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL;

ACNE VULGARIS; CONTRACEPTIVES, ORAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OSTEOPOROSIS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033910734     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation, 1998.
2. National Osteoporosis Foundation: Fast Facts on Osteoporosis. Washington, DC, National Osteoporosis Foundation, 1998.
3. Melton LJ III: Epidemiology of osteoporosis: predicting who is at risk. Ann New York Acad Sci 592:295-306, 1990.
4. Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650, 1993.
5. Centers for Disease Control: Osteoporosis among estrogen-deficient women - United States, 1988-1994. MMRW 47:969-973, 1998.
6. Shargil AA: Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three year prospective study. Int J Fertil 30:15-28, 1985.
7. Gambacciani M, Spinctti A, Taponeco F, et al: Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas 19:125-131, 1994.
8. Gambacciani M, Spinetti A, Taponeco F, et al: Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparaton on bone mineral density and metabolism. Obstet Gynecol 83:392-396, 1994.
9. Lindsay R, Tohme J, Kanders B: The effect of oral contraceptive use on vertebral bone mass in pre-and post-menopausal women. Contraception 34:333-340, 1986.
10. Enzelsberger H, Metka M, Heytmanek G, et al: Influence of oral contraceptive use on bone density in climacteric women. Maturitas 9:375-378, 1988.
11. Kleerekoper M, Brienza RS, Schultz LR, et al: The Henry Ford Hospital Osteoporosis Cooperative Research Group. Oral contraceptive use may protect against low bone mass. Arch Intern Med 151:1971-1976, 1991.
12. Kritz-Silverstein D, Barrett-Conner E: Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health 83:100-102, 1993.
13. Hergenroeder AC, O'Brian Smith E, et al: Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol 176:1017-1025, 1997.
14. Seeman E, Szmukler GI, Formica C, et al: Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res 7:1467-1474, 1992.
15. Haenggi W, Casez J-P, Birkhauser MH, et al: Bone mineral density in young women with long-standing amenorrhea: limited effect of hormone replacement therapy with ethinyl estradiol and desogestrel. Osteoporosis Int 4:99-103, 1994.
16. Goldsmith NF, Johnston JO: Bone mineral: effects of oral contraceptives, pregnancy, and lactation. J Bone Joint Surgery 57:657-668, 1975.
17. Hansen MA, Overgaard K, Riis BJ, et al: Potential risk factors for development of postmenopausal osteoporosis - examined over a 12-year period. Osteoporosis Int 1:95-102, 1991.
18. Laitinen K, Valimaki M, Keto P: Bone mineral density measured by dual-energy x-ray absorptiometry in healthy Finnish women. Calcif Tissue Int 48:224-231, 1991.
19. Masaryk P, Lunt M, Benevolenskaya L, et al: Effects of menstrual history and use of medications on bone mineral density: The EVOS Study. Calcif Tissue Int 63:271-276, 1998.
20. Michaelsson K, Baron JA, Farahmand BY, et al: Oralcontraceptive use and risk of hip fracture: a case-control study. Lancet 353:1481-1484, 1999.
21. Recker RR, Davies KM, Hinders SM, et al: Bone gain in young adult women. JAMA 268:2403-2408, 1992.
22. Sowers MR, Clark MK, Hollis B, et al: Radial bone mineral density in pre-and perimenopausal women: a prospective study of rates and risk factors for loss. J Bone Miner Res 7:647-657, 1992.
23. Stevenson JC, Lees B, Devenport M, et al: Determinants of bone density in normal women: risk factors for future osteoporosis? Br Med J 298:924-928, 1989.
24. Volpe A, Amram A, Cagnacci A, et al: Biochemical aspects of hormonal contraception: effects on bone metabolism. Eur J Contracep Reprod Health Care 2:123-136, 1997.
25. Fortney JA, Feldblum PJ, Talmage RV, et al: Bone mineral density and history of oral contraceptive use. J Reprod Med 39:105-109, 1994.
26. Volpe A, Silferi M, Genazzani AD, et al: Contraception in older women. Contraception 47:229-239, 1993.
27. Mais V, Fruzzetti F, Ajossa S, et al: Bone metabolism in young women taking a monophasic pill containing 20 mcg ethinyl estradiol: a prospective study. Contraception 48:445-452, 1993.
28. Mazess RB, Barden HS: Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth-control pills. Am J Clin Nutr 53:132-142, 1991.
29. Rodin A, Chapman M, Fogelman I: Bone density in users of combined oral contraception. Br J Fam Plann 16:125-129, 1991.
30. Castelo-Branco C, Martinez de Osaba MJ, Pons F, et al: Effects on bone mass of two oral contraceptives containing ethinyl estradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. Eur J Contracep Reprod Health Care 3:79-84, 1998.
31. Cromer BA, McArdle Blair J, et al: A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129:671-676, 1996.
32. Lloyd T, Buchanan JR, Ursino GR, et al: Long-term oral contraceptive use does not affect trabecular bone density. Am J Obstet Gynecol 160:404-404, 1989.
33. Collins CL, Thomas KA, Harding AF, et al: The effect of oral contraceptives on lumbar bone density in premenopausal women. J La State Med Soc 140:31-39, 1988.
34. Hall ML, Heavens J, Cullum ID, et al: The range of bone marrow density in normal British women. Br J Radiol 63:266-269, 1990.
35. Hreshchyshyn MM, Hopkins A, Zylstra S, et al: Associations of parity, breast-feeding, and birth control pills with lumbar spine and femoral neck bone densities. Am J Obstet Gynecol 159:318-322, 1988.
36. Johnell O, Nilsson BE: Life-style and bone mineral mass in perimenopausal women. Calcif Tissue Int 36:354-356, 1984.
37. Murphy S, Khaw KT, Compston JE: Lack of relationship between hip and spine bone mineral density and oral contraceptive use. Eur J Clin Invest 23:108-111, 1993.
38. Goulding A, McChesney R: Oestrogen-progestogen oral contraceptives and urinary calcium excretion. Clin Endocrinol 6:449-454, 1977.
39. Kitai E, Blum M, Kaplan B: The bone sparing effect of oral contraceptive use in non-smoking women. Clin Exp Obstet Gyn 19:30-33, 1992.
40. Sowers MFR, Wallace RB, Hollis BW, et al: Parameters related to 25-OH-D levels in a population-based study of women. Am J Clin Nutr 43:621-628, 1986.
41. Karlsson R, Eden S, van Schoultz B: Oral contraception affects osteocalcin serum profiles in young women. Osteoporosis Int 2:118-121, 1992.
42. Garnero P, Sorhay-Rendu E, Delmas PD: Decreased bone turnover in oral contraceptive users. Bone 16:499-503, 1995.
43. Mais V, Fruzzetti F, Ajossa S, et al: Bone metabolism in young women taking a monophasic pill containing 20 mcg ethinyl estradiol: a prospective study. Contraception 48:445-452, 1993.
44. Stern RS: The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 26:931-935, 1992.
45. Gupta MA, Gupta AK, Schork NJ, et al: Psychiatric aspects of the treatment of mild to moderate facial acne: some preliminary observations. Int J Dermatol 29:719-721, 1990.
46. Koo JYM, Smith LL: Psychologic aspects of acne. Pediatr Dermatol 8:185-188, 1991.
47. Lowe JG: The stigma of acne. Br J Hosp Med 49:809-812, 1993.
48. Van der Meeren HLM, van der Schaar WW, van den Hurk CMAM: The psychological impact of severe acne. Cutis 36:84-86, 1985.
49. Lucky AW: Hormonal correlate of acne on hirsutism. Am J Med 98(suppl 1A):89S-94S, 1995
50. Stern RS: Acne therapy. Medication use and sources of care in office-based practice. Arch Dermatol 132:776-780, 1996.
51. Burkman RT: The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 98(suppl 1A):130S-136S, 1995.
52. Lemay A, Dewailly SD, Grenier R, et al: Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low dose of ethinyl estradiol and d,l-norgesterel. J Clin Endocrinol Metab 71:8-14, 1990.
53. Mango D, Ricci S, Manna P, et al: Clinical and hormonal effects of ethinyl estradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 53:163-170, 1996.
54. Palatsi R, Hirvensalo E, Liukko P, et al: Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol (Stockh) 64:517-523, 1984.
55. Carlborg L: Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet Gynecol Scand 134:29-32, 1986.
56. Erkkola R, Hirvonen E, Luikku J, et al: Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 69:719-721, 1990.
57. Wishart JM: An open study of Triphasil and Diane 50 in the treatment of acne. Australas J Dermatol 32:51-54, 1991.
58. Lucky AW, Henderson TA, Olson WH, et al: Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37:746-754, 1997.
59. Redmond GP, Olson WH, Lippman JS, et al: Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89:615-622, 1997.